Association of Agent Orange and myeloproliferative neoplasms, thrombosis, and bleeding among veterans. Addition of venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with ...
The addition of ivosidenib (Tibsovo) to azacitidine led to a threefold survival improvement for newly diagnosed IDH1-mutant acute myeloid leukemia (AML) patients who were ineligible for intensive ...
Tibsovo plus Vidaza led to survival benefit for patients with IDH1-mutant acute myeloid leukemia, according to findings from the AGILE clinical trial. Findings from the phase 3 AGILE trial showed ...
A 1,563‑sample chromatin atlas reveals 16 epigenomic subgroups of AML, redefining disease classification, prognosis, and therapeutic vulnerabilities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results